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Towards universal inﬂuenza vaccines?
Ab Osterhaus*, Ron Fouchier and Guus Rimmelzwaan
Department of Virology, Erasmus MC, Rotterdam, The Netherlands
Vaccination is the most cost-effective way to reduce the considerable disease burden of seasonal
inﬂuenza. Although seasonal inﬂuenza vaccines are effective, their performance in the elderly and
immunocompromised individuals would beneﬁt from improvement. Major problems related to
the development and production of pandemic inﬂuenza vaccines are response time and production
capacity as well as vaccine efﬁcacy and safety. Several improvements can be envisaged. Vaccine
production technologies based on embryonated chicken eggs may be replaced by cell culture
techniques. Reverse genetics techniques can speed up the generation of seed viruses and new math-
ematical modelling methods improve vaccine strain selection. Better understanding of the correlates
of immune-mediated protection may lead to new vaccine targets besides the viral haemagglutinin,
like the neuraminidase and M2 proteins. In addition, the role of cell-mediated immunity could be
better exploited. New adjuvants have recently been shown to increase the breadth and the duration
of inﬂuenza vaccine-induced protection. Other studies have shown that inﬂuenza vaccines based on
different viral vector systems may also induce broad protection. It is to be expected that these devel-
opments may lead to more universal inﬂuenza vaccines that elicit broader and longer protection,
and can be produced more efﬁciently.
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1. INTRODUCTION
Seasonal, avian and pandemic inﬂuenza are three
manifestations of human inﬂuenza which all have a
different aetiology. However, the differences between
these forms of inﬂuenza are generally poorly under-
stood and appreciated [1]. Seasonal inﬂuenza or
‘winter ﬂu’ is an annually recurring acute respiratory
disease caused by an inﬂuenza A or B virus that affects
between 2.5 and 10 per cent of the population in
the moderate climate zones every year in the winter
months. Therefore, ‘winter ﬂu’ is associated with a
high burden of disease and especially people within
the so-called high-risk groups are more likely to
develop serious disease and complications leading to
increased morbidity and mortality. Seasonal inﬂuenza
viruses manage to persist in the human population
by a process called ‘antigenic drift’, which is based
on the high mutation rate that allows these viruses to
escape continuously from the antibodies that are
generated after each inﬂuenza virus infection. Avian
inﬂuenza is a sporadic form of inﬂuenza caused by
one of the many inﬂuenza A viruses from birds,
which are transmitted to humans either directly or
indirectly, e.g. through an intermediate mammalian
host like the pig. Although avian inﬂuenza may be a
serious disease in humans with a very high case fatality
rate, which is largely dependent on the viral subtype
involved, avian inﬂuenza viruses are not, or are not
efﬁciently, transmitted from human to human.
Therefore, the number of human cases and overall
burden of disease worldwide are relatively limited. If,
however, an avian inﬂuenza virus, through a process
of re-assortment and/or continuous mutation, does
acquire the ability to spread from human to human
efﬁciently, it may cause a worldwide or pandemic
outbreak of inﬂuenza. In the past century, more than
50 million people have died during the four inﬂuenza
pandemics that hit the world in 1918 (‘Spanish ﬂu’),
1957 (‘Asian ﬂu’), 1968 (‘Hongkong ﬂu’) and 2009
(‘swine or Mexican ﬂu’), respectively. It is, however,
estimated that between these pandemics at least the
same number of people have died worldwide from
seasonal inﬂuenza.
Although societal interventions, like the implemen-
tation of hygienic measures and the closure of schools
and social events, may reduce the spread of inﬂuenza,
medical interventions to combat disease largely rely on
surveillance, rapid diagnostics, dedicated clinical care
and the use of vaccines and antivirals. Preventive
vaccination is by far the most cost-effective way to
combat seasonal inﬂuenza, although there is also
room for improvement. Vaccine effectiveness in pre-
venting laboratory-conﬁrmed inﬂuenza illness when
the vaccine strains are well matched to circulating
strains is 70–90% in randomized, placebo-controlled
trials conducted among children and young healthy
adults, but is lower among elderly or immunocom-
promised persons. In years with a suboptimal match,
vaccine beneﬁt is likely to be lower, although the vac-
cine can still provide substantial beneﬁt, especially
against more severe outcomes [2,3].
Combating sporadic human cases of avian inﬂuenza
is largely dependent on veterinary control measures
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and vaccination policies for poultry in endemic or at
risk areas, and the implementation of poultry culling
strategies [4–9]. Hygienic measures in endemic areas
should further reduce the risk of human exposure.
Rapid laboratory diagnosis and specialized clinical
care with the use of the correct antiviral regimens are
needed to treat infected patients and limit the case
fatality rate [10]. Human vaccination against avian
and pandemic inﬂuenza is much more difﬁcult to real-
ize since currently no registered human vaccines are
available and the seasonal inﬂuenza vaccines offer no
protection against viruses from other subtypes.
Although the feasibility of pre-pandemic vaccination
strategies against certain avian inﬂuenza viruses ‘with
high pandemic potential’ has been explored, the
unpredictability of the emergence of pandemic viruses
seriously limits this approach. Therefore there is an
urgent need for the development of new generation
inﬂuenza vaccines that offer broader protection, not
only to emerging drift variants of seasonal inﬂuenza
viruses, but preferably also to inﬂuenza A virus of
different inﬂuenza A virus subtypes that regularly
infect birds and mammals and may be the basis of
future inﬂuenza pandemics. More ‘universal vaccines’
that offer broader and long-lived protection should
therefore be considered the major challenge for the
development of new generation inﬂuenza vaccines.
2. VACCINATION AGAINST SEASONAL
INFLUENZA
Inﬂuenza vaccination is the most cost-effective way to
reduce the disease burden from seasonal inﬂuenza.
Inactivated seasonal inﬂuenza vaccines have been used
for this purpose since the 1940s. They are administered
intramuscularly and may be given to individuals from
six months of age onward. Alternatively, live attenuated
inﬂuenza vaccine (LAIV) and cold-adapted inﬂuenza
vaccine are administered intranasally and have been
used in some countries since the 1960s [3]. In many
countries, special recommendations and guidelines are
in place for the vaccination of individuals in the so-
called high-risk groups for inﬂuenza. These individuals
may suffer from more serious disease and are more
prone to develop severe complications when infected
with seasonal inﬂuenza viruses. These groups classically
include patients with chronic cardiovascular disease,
chronic airway disease, diabetes mellitus, chronic
renal dysfunction, immunocompromised individuals
and the elderly. As the worldwide burden of seasonal
inﬂuenza disease is substantial, the World Health
Organization (WHO) has indicated that member
states should evaluate the cost-effectiveness of introdu-
cing inﬂuenza vaccination into national immunization
programmes [3].
There are several more speciﬁc recommendations
for vaccination coverage by the WHO and the Euro-
pean Commission which advocate ideally aiming at a
vaccination coverage of 75 per cent in the high-risk
groups. Although some countries in North America
and Europe have now indeed achieved such coverage
rates, in most countries seasonal inﬂuenza vaccination
does not have such a high public health priority. In
the USA and Canada, however, more universal vacci-
nation strategies that target the whole population have
now been adopted.
Inactivated and LAIV seasonal inﬂuenza vaccines
that are used today are virtually all formulated with
viral antigens produced in embryonated chicken
eggs. This technology was developed more than 60
years ago and has so far not been replaced by state-
of-the-art in vitro cell culture techniques. The virus
that is produced in the allantoic ﬂuid of the embryon-
ated chicken eggs is subsequently puriﬁed and
inactivated to serve as whole inactivated inﬂuenza
vaccine, after detergent treatment as split whole virus
inﬂuenza vaccine, or after additional puriﬁcation as
subunit inﬂuenza vaccines. Also, LAIVs are produced
by propagating attenuated inﬂuenza viruses in
embryonated chicken eggs. Vaccination is primarily
aimed at the induction of protective antibodies
directed against the haemagglutinin (HA) and neur-
aminidase (NA). Antibodies against the HA are
generally considered to be the major correlate of
protection against the disease (table 1).
The main challenge in the production of seasonal
inﬂuenza vaccines is to identify the inﬂuenza A and
B viruses that will most probably be circulating in
the next inﬂuenza season. A unique worldwide surveil-
lance system coordinated by WHO that monitors and
characterizes circulating seasonal inﬂuenza viruses in
all continents serves to identify the most likely virus
candidates that should be represented in the vaccine
for the coming season. This happens twice per year
for the Northern and the Southern Hemispheres,
respectively. This system has recently been comple-
mented with real-time monitoring and mathematical
modelling systems for seasonal inﬂuenza virus strains
as they emerge [11,12]. This system not only allows
a more adequate identiﬁcation, visualization and com-
parison of newly arising drift variants of seasonal
inﬂuenza viruses, but also allows the actual measure-
ment of antigenic distances between existing and
newly emerging inﬂuenza viruses. These real-time
data provide an increasingly important aid in the
identiﬁcation of the best-ﬁtting viral vaccine strains
for the next inﬂuenza season.
The safety record of seasonal inﬂuenza vaccines is
exceptionally good. The most common adverse event
associated with inactivated vaccines is local reactogen-
icity at the site of injection, while systemic reactogenicity
such as fever or malaise is less common. Adverse events
associated with LAIVarenasal congestion and symptoms
of mild inﬂuenza such as headache, myalgias and fever.
LAIVadministration may cause increased risk of wheez-
ing in young children and the elderly. For review, see [3].
Seasonal inﬂuenza vaccines have been shown to
be effective, especially in young and healthy individ-
uals. However, in immunocompromised individuals,
most of whom are over-represented in the high-risk
groups, the effectiveness of the currently used seasonal
inﬂuenza vaccines is considerably lower. Therefore,
improvement of the effectiveness of seasonal inﬂuenza
vaccines for the high-risk groups is a major research
priority. It may be anticipated that the efforts aimed
at the improvement of the effectiveness and breadth
of pre-pandemic and pandemic inﬂuenza vaccines, as
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ment of the effectiveness of seasonal inﬂuenza
vaccines. For example, one of the seasonal inﬂuenza
vaccines currently used in the elderly contains the adju-
vant MF59 that is claimed to have an enhancing effect
on the longevity of the antibody response in the elderly
and may thus provide longer protection (G. Del
Giudice 2010, personal communication). It should,
however, be realized that adjuvants in general only pro-
vide limited immune enhancing effect in individuals
who have already been primed by infection or vacci-
nation [13–15]. Furthermore, the annually repeated
use of an adjuvant in seasonal inﬂuenza vaccines
might carry an additional accumulating risk of causing
adverse events. For these reasons, the development of
more broadly reactive and longer-acting seasonal inﬂu-
enza vaccines should also focus on additional and novel
approaches that are also explored for the generation of
new generation pre-pandemic and pandemic vaccines,
as described in §3a.
Finally, it is important to highlight that animal
models are crucial for the preclinical evaluation of
novel candidate inﬂuenza vaccines. In most cases, a
tier of multiple animal models is used before the
evaluation of vaccine candidates in clinical trials is
considered. Commonly, vaccines are tested for safety
and efﬁcacy in mice, ferrets and/or macaques [16].
3. VACCINATION AGAINST PANDEMIC
INFLUENZA
(a) Pre-pandemic and pandemic inﬂuenza
vaccines
The main problem in developing and producing pre-
pandemic or pandemic vaccines is that the virus that
will cause the next pandemic is not known in advance.
Given the unpredictable nature and high variability of
inﬂuenza viruses, it is hard to anticipate which inﬂu-
enza virus from which animal species will be at its
base. This was best illustrated by the pandemic pre-
paredness efforts that were implemented by many,
predominantly industrialized, countries in the past
decade. In the prelude to the 2009 H1N1 inﬂuenza
pandemic, the world largely focused on the pandemic
threat posed by the highly pathogenic avian inﬂuenza
virus of the H5N1 subtype (HPAI-H5N1 virus)
which, since 2003, had claimed hundreds of victims
from zoonotic transmissions, mainly in South East
Table 1. Arms of the adaptive immune system and their viral targets that contribute to protective immunity against
inﬂuenza.
arm of the
immune system viral target remarks vaccine type
antibodies HA antibodies speciﬁc for the globular head
containing the receptor binding region can
neutralize the virus
any vaccine containing this
component
primary correlate of protection
vaccine-induced antibodies need to match the
epidemic strain
NA antibodies inhibit virus replication by inhibiting
NA activity and spread of virus
any vaccine containing this
component
vaccine-induced antibodies need to match the
epidemic strain
M2 relatively conserved
basis for more universal vaccine?
antibodies are not virus-neutralizing
speciﬁc immunogen
targeting the induction
of these antibodies
protective effect involves antibody-dependent
cell-mediated cytotoxicity
HA stem relatively conserved
basis for more universal vaccine?
speciﬁc immunogen
targeting the induction
of these antibodies
NP relatively conserved, protective effect
demonstrated in the presence of virus-speciﬁc
T cells
any vaccine containing this
component
mode of action largely unknown
CD4
þ T cells all viral proteins essential for mounting robust virus B cell and
CTL responses
any vaccine containing or
expressing viral proteins
direct action against infected cells
CD8
þ T cells predominantly internal
proteins, e.g. NP
and M1
internal proteins are relatively conserved
therefore, majority of virus-speciﬁc CD8
þ
T cells are cross-reactive and contribute to
heterosubtypic immunity
live attenuated vaccines
vector vaccines expressing
internal proteins
DNA vaccines
basis for more universal vaccine? special adjuvant systems
key role in elimination of virus- infected cells
efﬁcient induction of CD8
þ T cells requires
endogenous antigen processing and
presentation
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human to human [17]. Pre-pandemic candidate
H5N1 vaccines were developed and tested in clinical
trials and pre-clinically in ferret vaccination challenge
experiments (see below).
Even with the available technologies and the
implemented pandemic preparedness plans, it took
more than six months to produce the ﬁrst vaccine
doses against the unexpected 2009 pandemic H1N1
(pdm H1N1) virus. This virus was ﬁrst detected in
Mexico and emerged as the consequence of a reassort-
ment event between Eurasian and North American
swine viruses [18]. For those countries that were ﬁrst
hit by the emerging pandemic, like those in the
Southern Hemisphere, but also for some countries in
the Northern Hemisphere, the vaccines clearly came
too late and well after the pandemic struck. For
other countries, the 2009 pdm H1N1 vaccines
became available just before or during the peak of
the pandemic. It should, however, be emphasized
that this pandemic outbreak of inﬂuenza was the ﬁrst
during which people, albeit only in certain countries,
could actually be vaccinated with pandemic vaccines.
If the pandemic virus had been identiﬁed one month
earlier, this would have made a difference in terms of
the number of people that could be vaccinated in time.
Besides having a surveillance and early warning
system in place, the three key issues related to the even-
tual availability of pandemic inﬂuenza vaccines are
(i) response time from the moment the pandemic
virus is identiﬁed, (ii) vaccine production capacity,
and (iii) efﬁcacy as well as safety of the pandemic
vaccines concerned. The last also requires special pan-
demic preparedness of regulatory authorities. With the
currently available technologies, the response time
until the ﬁrst doses of vaccine become available
is apparently more than six months, after which large-
scale production of the vaccines will take many
additional months. The overall worldwide production
capacity for pandemic inﬂuenza vaccines is largely
dependent on the production of seasonal inﬂuenza vac-
cines, which today may be estimated to approximate
about 900 million doses of trivalent inﬂuenza vaccine
per year. If all this capacity could indeed be used,
about 2.7 billion doses of monovalent inﬂuenza vaccine
could be produced. It has, however, become clear that
with the currently used inactivated formulations of
seasonal inﬂuenza vaccines, whole inactivated, split
and subunit vaccines, which use about 15 mgo fv i r a l
HA per vaccine dose, no protective immune response
can be obtained in individuals who are naive towards
the pandemic virus. Using avian H5N1 viral antigen
in clinical trials, it was shown that two vaccinations
with at least 90 mg of HA were needed to induce the
required antibody response, although this dose could
be considerably reduced by the inclusion of an adjuvant
[19]. Obviously, this reduces the available pandemic
inﬂuenza vaccine production capacity dramatically.
Besides these key issues, there are numerous additional
logistic problems in vaccinating whole populations
against a rapidly spreading inﬂuenza virus. These
should all be addressed in pandemic preparedness
plans that, according to WHO recommendations, each
country should have in operation.
4. NOVEL APPROACHES USING EXISTING
VACCINE FORMULATIONS
The inﬂuenza vaccine production technologies used
today are virtually all based on the use of embryon-
ated chicken eggs for the production of viral antigen.
Obviously, this more than 60 year old approach has
performed well over time but now clearly suffers from
lack of ﬂexibility and rapid up-scaling possibilities.
Novel technologies that are now being explored and
implemented, both in pre-clinical and clinical studies,
include the use of continuous mammalian cell lines
such as Madin Darby canine kidney (MDCK) cells,
Vero cells and PERC-6 cells (table 2). Also, the use of
inﬂuenza virus HA produced in plant cells or with bacu-
lovirusproductionsystemsarecurrentlybeingtested.All
these approaches may increase the availability of the
production substrate.
Vaccine seed viruses are classically produced by
reassortment methods using the circulating inﬂuenza
viruses against which the vaccine should be produced
together with production substrate-adapted inﬂuenza
viruses. This is a time consuming and rather unpre-
dictable procedure that is now being replaced by
faster and more efﬁcient reverse genetics techniques
that have been developed in the past decade. The
use of the novel reverse genetics approaches is subject
to intellectual property rights.
Virus strain selection for seasonal inﬂuenza vaccines
is based on the data generated by the inﬂuenza surveil-
lance network that is coordinated by WHO through
its worldwide network of afﬁliated national inﬂuenza
centres and collaborating centres. On the basis of the
epidemiological, virological and clinical data collected
by the network, recommendations on vaccine strain
selection are made twice per year to the vaccine manu-
facturers. In recent years, the surveillance system has
been greatly improved by the implementation of real-
time collection of the data and the use of antigenic
cartography [20]. These methods are now also being
implemented for the surveillance of avian and mamma-
lian inﬂuenza viruses, which may be the basis of future
pandemic viruses. Based on these data, repositories of
animal seed strain viruses can be generated that serve
to produce candidate pandemic vaccines rapidly when
a pandemic virus arises from the animal world [21].
5. NOVEL APPROACHES USING NEWLY
IDENTIFIED CORRELATES OF PROTECTION
To date, the only correlate of immune-mediated protec-
tionagainst inﬂuenzathat isused for the productionand
quality assessment of inﬂuenza vaccines is the induction
ofantibodiesagainsttheHAofthevirus.Ithas,however,
been demonstrated that the NA can also induce protec-
tive immunity (table 1). It was shown recently in ferret
vaccination challenge experiments that candidate vac-
cines based on iscom-matrix-adjuvanted soluble HAs
and NAs were equally protective against 2009 pdm
H1N1 virus challenge. The inclusion of NA in a vaccine
is therefore likely to reduce the HA dose required and to
broaden the protective immunity [22].
To date, 16 HAs have been identiﬁed and only nine
NAs (which are also more conserved than HAs), so
the use of NA as an additional vaccine immunogen
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tory authorities request the presence of NA in seasonal
inﬂuenza vaccines, there are, unlike for the HA, no
requirements for its quantiﬁcation or quality assurance.
It was recently shown that a new generation of
mouse and human virus neutralizing monoclonal anti-
bodies, reactive with an epitope located in the stem
region of the HA molecule and shared by the haem-
agglutinins of H1, H2, H5, H6 and H9 subtypes of
inﬂuenza A virus, has prophylactic and therapeutic
efﬁcacy against severe HPAI-H5N1 virus infection in
ferrets. This justiﬁes the expectation that the epitope
recognized by this antibody could also induce broad-
neutralizing antibodies when incorporated as an
immunogen in inﬂuenza vaccines aiming at a vaccine
inducing broader cross-protection [23–25].
Another strategy that has been studied is targeting
of the ectodomain of the M2 protein as an immuno-
gen. M2 protein is a small membrane protein of
inﬂuenza A viruses only, which upon natural infection
does not induce protective antibodies. However, when
used as an isolated immunogen, it has been shown to
elicit protective antibodies in animal studies under
certain conditions. This protection has been claimed
to be broad as the M2 protein is relatively well con-
served and therefore it could also contribute to the
development of a more ‘universal vaccine’ [26].
Besides the induction of protective antibodies with
the HA, the NA or the M2 proteins of inﬂuenza
viruses, the induction of protective T cell responses
should also be seriously considered (table 1). Although
in recent years, it has been documented that protective
T helper cell responses and cytotoxic T cell responses
can be induced in animal model systems, the data on
protective T cell responses in humans have remained
more circumstantial for obvious reasons [27,28].
However, the identiﬁcation of targets for the induction
of protective T cell responses should also be con-
sidered an attractive approach. This would include
the identiﬁcation of internal viral proteins with con-
served epitopes and the identiﬁcation of efﬁcient
modes of delivery to induce these responses. These
include the use of vector systems, live attenuated
viruses, certain adjuvant systems and DNA-based
vaccine candidates. As these approaches target predom-
inantly conserved T cell epitopes, they may also be
expected to contribute to the development of more uni-
versal or hetero-subtypic cross-protective vaccines. In
several mouse models, it has been shown that pre-infec-
tion with a virus that shares all proteins with a lethal
challenge virus but not the HA and the NA, may, in
spite of not preventing considerable weight loss, still
offer protection from a fatal outcome of the challenge
infection [29]. Also when the internal viral proteins
are only partially shared, protection from fatal challenge
infection can still be observed [30]. The observed pro-
tection in these experiments has been shown to
correlate strongly with virus-speciﬁc T cell responses
including CD8
þ T cell responses in, e.g. adoptive trans-
fer and tetramer staining experiments.
In addition to these mouse data, it was shown in
humans that cytotoxic T lymphocytes (CTLs) speciﬁc
for, e.g. seasonal inﬂuenza viruses, display high cross-
reactivity with HPAI-H5N1 viruses [31]. Collectively,
these observations indicate that targeting cross-reactive
CTL epitopes may also be a base for the development
of a more universal inﬂuenza vaccine.
Although at least some of the T cell-mediated
immunity induced by either vaccination or natural
infection cannot be expected to be fully protective, it
could still contribute to a signiﬁcant degree of clinical
protection, which for both seasonal and pandemic
inﬂuenza vaccines may still be important.
6. SEASONAL INFLUENZA VACCINATION AND
SUBSEQUENT AVIAN OR PANDEMIC INFLUENZA
In mouse and ferret experiments, it was recently shown
that vaccination against seasonal H3N2 inﬂuenza virus
protects against infection with this seasonal inﬂuenza
virus but consequently also limits the induction of
heterosubtypic T cell-mediated immunity that is elicited
Table 2. Recent developments to improve the timely availability of efﬁcacious (pandemic) inﬂuenza vaccines.
development remarks
production of seed strains use of reverse genetics especially relevant for the preparation of safe vaccine strains
against highly pathogenic avian inﬂuenza
removal of basic cleavage site by site-directed mutagenesis
production platform use of cell lines various cell-culture systems have been established using MDCK,
VERO or PERC6 cells
vaccine formulations recombinant proteins in addition to existing inactivated vaccine formulations (whole
virus, split virion and subunit)
live attenuated
vaccines
production of recombinant proteins in insect cells using
baculovirus expression system
attenuation of live viruses by cold-adaptation (e.g. Flumist) or
defective NS1 gene
increasing immunogenicity/
dose sparing
use of adjuvants use of oil-in-water adjuvants like MF59 and ASO3 improve
immunogenicity
allow dose sparing
alternative antigen delivery
systems
establishment of viral
vectors
recombinant adenovirus and poxviruses expressing inﬂuenza virus
genes (e.g. HA)
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vaccinated against seasonal H3N2 inﬂuenza virus prior
toH3N2inﬂuenzavirusinfectionprovedtobemoresus-
ceptible to subsequent fatal infection with HPAI-H5N1
infection [32–34]. It has been speculated that a similar
mechanism could underlie the observation that in some
countries individuals vaccinated against seasonal inﬂu-
enza, but not against pandemic 2009 H1N1 inﬂuenza,
appeared to be more susceptible to developing severe
pandemic 2009 H1N1 inﬂuenza than those that
had not been vaccinated against seasonal inﬂuenza
[35–37]. Whether this was indeed the case is not clear
at this moment, but it may still be concluded that chil-
dren vaccinated against seasonal inﬂuenza should also
be vaccinated against pandemic inﬂuenza when it
arises. It should, however, be realized that with the cur-
rently available technology, a pandemic vaccine will not
be available for some time after the pandemic starts.
Therefore, the mechanism underlying this observa-
tion should be elucidated and in this light a thorough
risk–beneﬁt evaluation should be carried out when
vaccination of all children against seasonal inﬂuenza, as
is now recommended in some countries, is routinely
implemented.
7. NOVEL APPROACHES USING ADJUVANTS
Several adjuvants are used in animal vaccines with the
aim of improving their protective efﬁcacy in terms of
level, breadth and duration of protection, at the cost
of a relatively limited increase of adverse events.
Although many veterinary vaccines used today are adju-
vanted with more or less complex adjuvants or adjuvant
systems, only a few seasonal inﬂuenza vaccines for
humans are adjuvanted. This is in part related to the
observation mentioned above, that adjuvants usually
provide limited immune enhancing effect to vaccines
in individuals who have already been primed by infec-
tion or vaccination. Although there are a large number
of adjuvants and adjuvant systems that have shown
promise in animal models, an unacceptable increase in
adverse effects has in most cases limited their appli-
cation in human vaccines. However, a new generation
of proprietary oil in water adjuvants like MF59 and
AS03 has shown great promise when tested pre-clini-
cally in ferrets and clinically with HPAI-H5N1
antigens. After the start of the 2009 inﬂuenza pandemic,
candidate vaccines formulated with these adjuvants
were ﬁrst tested in ferret challenge models. It was ﬁrst
shown that indeed two doses of as little as 2–4 mgo f
MF59- or AS03-adjuvanted pandemic vaccine would
elicit complete protection from challenge with 2009
pdm H1N1 virus. In these experiments, it was also
shown that vaccination with seasonal H1N1 vaccine
was not protective, but did provide a signiﬁcant priming
effect to the pandemic vaccination in ferrets [38,39].
This was in agreement with the ﬁnding that relatively
young people were more likely to develop serious 2009
pdm H1N1 virus infection than elderly people. It was
subsequently shown in clinical studies that one vacci-
nation with these adjuvanted vaccines was sufﬁcient to
reach the regulatory geometric mean titre (GMT), sero-
conversion rate (SCR) and seroprotection rate (SPR)
thresholds. Close monitoring of the safety of the
adjuvanted vaccines used during the last pandemic
showed an overall expected and acceptable increase of
local and systemic adverse events as judged
by national and international evaluation bodies. An
increased incidence of narcolepsy in children vaccinated
with one of these adjuvanted vaccines in Finland and
Sweden and possibly other European countries is cur-
rently under investigation [40,41]. About 250 cases of
narcolepsy were identiﬁed among 20 million people
who had been vaccinated with this vaccine, but a
causal relationship has not yet been conﬁrmed [42].
In conclusion, it may be stated that the new gener-
ation adjuvants have a clear antigen sparing effect on
pandemic vaccines that is, however, less pronounced
in individuals who have been primed earlier in their
lives with antigenically related viruses or vaccines. It
has, therefore, also led to a signiﬁcant antigen sparing
effect on 2009 pdm H1N1 vaccines.
8. NOVEL APPROACHES USING VECTORS
FOR ANTIGEN DELIVERY
Several replication-competent and -impaired viruses as
well as bacteria and virus-like particles, plasmid DNA,
autologous dendritic cells as professional antigen-
presenting cells and exosomes have been studied as
delivery vehicles for antigen delivery in animal models.
Recombinant adenoviruses and poxviruses appear to
be among the most promising candidates for both
human and veterinary inﬂuenza vaccines. A promising
candidate vaccine vector is modiﬁed vaccinia virus
Ankara (MVA), originally developed as a safe smallpox
vaccine, which can be exploited as a viral vector and
has many favourable properties. It has been used to
express inﬂuenza virus nucleoprotein, matrix protein
and HA. These vaccine candidates have now been
tested in several mouse, macaque and ferret vaccination
challenge experiments in which it was shown that
broad and long-lasting immunity against seasonal,
HPAI-H5N1 and 2009 pdm H1N1 viruses could be
induced with virtually no side effects [30,43–47].
Furthermore, the ﬁrst clinical studies with a MVA
candidate vaccine expressing the inﬂuenza virus nucleo-
protein and the M1 protein have been performed and it
was shown that this vaccine is immunogenic and elicited
virus-speciﬁc CD8
þ T cell responses [48].
9. CONCLUSION
Seasonal inﬂuenza vaccines have a good safety and
effectiveness record. However, there is clearly room
for improvement as these vaccines are least effective
in those who need them the most: frail, elderly and
immunocompromised individuals. In 2009, vaccines
for pandemic inﬂuenza have for the ﬁrst time in history
become available during an inﬂuenza pandemic.
Although these vaccines also proved to be highly effect-
ive and safe, for many countries they came too late or
only became available well into the pandemic. For
more than half a century, inﬂuenza vaccines have been
produced with classical technology dependent on the
use of embryonated chicken eggs, and the technologies
used have so far have proﬁted little from the revolution
that is taking place in the ﬁeld of vaccine biotechnology.
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duced for pandemic inﬂuenza and to a lesser extent for
seasonalinﬂuenza,andseveralnovelgenerationsofinﬂu-
enza vaccines are currently being developed. This may
eventuallyleadtobroaderandlonger protective vaccines
that can be produced faster and more efﬁciently. It may
be expected that both seasonal and pandemic inﬂuenza
vaccines will beneﬁt greatly from these developments in
the near future.
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